(URGN) UroGen Pharma - Overview
Stock: Jelmyto, UGN-102, UGN-103, UGN-104, UGN-301
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 66.8% |
| Relative Tail Risk | -17.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.11 |
| Alpha | 66.99 |
| Character TTM | |
|---|---|
| Beta | 1.068 |
| Beta Downside | 0.986 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.64% |
| CAGR/Max DD | 0.40 |
Description: URGN UroGen Pharma January 27, 2026
UroGen Pharma Ltd. (NASDAQ: URGN) focuses on developing and commercializing polymer-based hydrogel delivery systems for urothelial and specialty cancers, leveraging its proprietary reverse-thermal gelation technology (RTGel). Its commercial product Jelmyto (UGN-102) is approved for low-grade upper-tract urothelial carcinoma, while the pipeline includes UGN-103 (intravesical), UGN-104 (pyelocalyceal) and early-stage candidates UGN-301 ± UGN-201 or gemcitabine targeting high-grade NMIBC.
As of the latest Q4-2024 filing, URGN reported $71 million of cash and equivalents, a net loss of $28 million for the quarter, and a market capitalization of roughly $250 million. Phase 3 data for UGN-103 presented at the 2024 ASCO meeting showed a 71 % complete response rate at 12 months in a cohort of 45 patients, narrowing the efficacy gap with standard intravesical BCG therapy. The company also secured a licensing partnership with Agenus Inc. to expand intravesical delivery of Agenus’s immuno-oncology assets, potentially diversifying its revenue stream.
Sector-wide, US biotechnology firms have benefited from an 8 % year-over-year increase in R&D spending and a tightening cash-flow environment that favors companies with near-term commercial products, positioning UroGen’s approved Jelmyto as a strategic cash-generating asset amid this backdrop.
For a deeper quantitative assessment of URGN’s valuation dynamics, consider exploring the detailed analyst models on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -164.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.75 > 0.02 and ΔFCF/TA -42.70 > 1.0 |
| NWC/Revenue: 130.9% < 20% (prev 293.5%; Δ -162.7% < -1%) |
| CFO/TA -0.74 > 3% & CFO -137.7m > Net Income -164.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.1m) vs 12m ago 11.50% < -2% |
| Gross Margin: 87.95% > 18% (prev 0.90%; Δ 8705 % > 0.5%) |
| Asset Turnover: 39.64% > 50% (prev 29.60%; Δ 10.04% > 0%) |
| Interest Coverage Ratio: -5.36 > 6 (EBITDA TTM -130.7m / Interest Expense TTM 24.7m) |
Altman Z'' -15.00
| A: 0.68 (Total Current Assets 168.5m - Total Current Liabilities 42.2m) / Total Assets 185.0m |
| B: -5.04 (Retained Earnings -933.4m / Total Assets 185.0m) |
| C: -0.54 (EBIT TTM -132.5m / Avg Total Assets 243.5m) |
| D: -3.11 (Book Value of Equity -933.2m / Total Liabilities 300.5m) |
| Altman-Z'' Score: -18.88 = D |
Beneish M -2.49
| DSRI: 0.80 (Receivables 19.7m/22.8m, Revenue 96.5m/89.4m) |
| GMI: 1.03 (GM 87.95% / 90.27%) |
| AQI: 2.30 (AQ_t 0.04 / AQ_t-1 0.02) |
| SGI: 1.08 (Revenue 96.5m / 89.4m) |
| TATA: -0.15 (NI -164.6m - CFO -137.7m) / TA 185.0m) |
| Beneish M-Score: -2.49 (Cap -4..+1) = BBB |
What is the price of URGN shares?
Over the past week, the price has changed by +8.87%, over one month by -2.47%, over three months by -9.30% and over the past year by +94.98%.
Is URGN a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the URGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.3 | 65.1% |
| Analysts Target Price | 35.3 | 65.1% |
| ValueRay Target Price | 25.9 | 21.4% |
URGN Fundamental Data Overview February 02, 2026
P/B = 19.2691
Revenue TTM = 96.5m USD
EBIT TTM = -132.5m USD
EBITDA TTM = -130.7m USD
Long Term Debt = 122.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.59m USD (from shortTermDebt, last quarter)
Debt = 129.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.9m USD (from netDebt column, last quarter)
Enterprise Value = 920.8m USD (917.9m + Debt 129.9m - CCE 127.0m)
Interest Coverage Ratio = -5.36 (Ebit TTM -132.5m / Interest Expense TTM 24.7m)
EV/FCF = -6.67x (Enterprise Value 920.8m / FCF TTM -138.1m)
FCF Yield = -15.00% (FCF TTM -138.1m / Enterprise Value 920.8m)
FCF Margin = -143.1% (FCF TTM -138.1m / Revenue TTM 96.5m)
Net Margin = -170.6% (Net Income TTM -164.6m / Revenue TTM 96.5m)
Gross Margin = 87.95% ((Revenue TTM 96.5m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Gross Margin QoQ = 88.07% (prev 85.34%)
Tobins Q-Ratio = 4.98 (Enterprise Value 920.8m / Total Assets 185.0m)
Interest Expense / Debt = 6.15% (Interest Expense 7.99m / Debt 129.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -104.7m (EBIT -132.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.99 (Total Current Assets 168.5m / Total Current Liabilities 42.2m)
Debt / Equity = -1.13 (negative equity) (Debt 129.9m / totalStockholderEquity, last quarter -115.4m)
Debt / EBITDA = -0.31 (negative EBITDA) (Net Debt 39.9m / EBITDA -130.7m)
Debt / FCF = -0.29 (negative FCF - burning cash) (Net Debt 39.9m / FCF TTM -138.1m)
Total Stockholder Equity = -66.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.62% (Net Income -164.6m / Total Assets 185.0m)
RoE = 249.4% (negative equity) (Net Income TTM -164.6m / Total Stockholder Equity -66.0m)
RoCE = -236.2% (out of range, set to none) (EBIT -132.5m / Capital Employed (Equity -66.0m + L.T.Debt 122.1m))
RoIC = -186.6% (out of range, set to none) (NOPAT -104.7m / Invested Capital 56.1m)
WACC = 9.23% (E(917.9m)/V(1.05b) * Re(9.85%) + D(129.9m)/V(1.05b) * Rd(6.15%) * (1-Tc(0.21)))
Discount Rate = 9.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.29%
Fair Price DCF = unknown (Cash Flow -138.1m)
EPS Correlation: 68.97 | EPS CAGR: 83.04% | SUE: 3.38 | # QB: 1
Revenue Correlation: 87.46 | Revenue CAGR: 15.18% | SUE: -2.99 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.45 | Chg30d=+0.060 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.97 | Chg30d=-0.374 | Revisions Net=-1 | Growth EPS=+69.2% | Growth Revenue=+110.7%